Activation of MET promotes resistance to sorafenib in hepatocellular carcinoma cells via the AKT/ERK1/2-EGR1 pathway

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. Mar doi:10.3322/caac.21262.
   PubMed Web of Science ®Google Scholar
• Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist. 2006;11:790–800.
   PubMed Web of Science ®Google Scholar
• Lai EC, Fan ST, Lo CM, et al. Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg. 1995;221:291–298.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–1917.
   PubMed Web of Science ®Google Scholar
• Kudo M. Systemic therapy for hepatocellular carcinoma: 2017 update. Oncology. 2017;93:135–146.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.
   PubMed Web of Science ®Google Scholar
• Palmer DH. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:2498–2499.
   PubMed Web of Science ®Google Scholar
• Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol. 2010;11:834–848.
   PubMed Web of Science ®Google Scholar
• Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4:915–925.
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039–1043.
   PubMed Web of Science ®Google Scholar
• Bouattour M, Raymond E, Qin S, et al. Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma. Hepatology. 2018;67:1132-1149. doi:10.1002/hep.29496.
   Web of Science ®Google Scholar
• Gao JJ, Inagaki Y, Xue X, et al. c-Met: a potential therapeutic target for hepatocellular carcinoma. DD&T. 2011;5:2–11.
   Google Scholar
• Heynen GJ, Fonfara A, Bernards R. Resistance to targeted cancer drugs through hepatocyte growth factor signaling. Cell Cycle. 2014;13:3808–3817.
   PubMed Web of Science ®Google Scholar
• Xiang Q, Chen W, Ren M, et al. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET. Clin Cancer Res. 2014;20:2959–2970.
   PubMed Web of Science ®Google Scholar
• Cheng JC, Chang HM, Leung PC. Egr-1 mediates epidermal growth factor-induced downregulation of E-cadherin expression via Slug in human ovarian cancer cells. Oncogene. 2013;32:1041–1049.
   PubMed Web of Science ®Google Scholar
• Ozen E, Gozukizil A, Erdal E, et al. Heparin inhibits hepatocyte growth factor induced motility and invasion of hepatocellular carcinoma cells through early growth response protein 1. PLoS One. 2012;7:e42717.
   PubMed Web of Science ®Google Scholar
• Chen HA, Kuo TC, Tseng CF, et al. Angiopoietin-like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma. Hepatology. 2016;64:1637–1651.
   PubMed Web of Science ®Google Scholar
• Xiang QF, Zhang DM, Wang JN, et al. Cabozantinib reverses multidrug resistance of human hepatoma HepG2/adr cells by modulating the function of P-glycoprotein. Liver Int. 2015;35:1010–1023.
   PubMed Web of Science ®Google Scholar
• Xiang Q, Zhen Z, Deng DY, et al. Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma. J Exp Clin Cancer Res. 2015;12:118.
   Web of Science ®Google Scholar
• Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006;66:11851–11858.
   PubMed Web of Science ®Google Scholar
• van Malenstein H, Dekervel J, Verslype C, et al. Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth. Cancer Lett. 2013;329:74–83.
   PubMed Web of Science ®Google Scholar
• Chow AK, Ng L, Lam CS, et al. The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance. PLoS One. 2013;8:e78675.
   PubMed Web of Science ®Google Scholar
• Chen KF, Chen HL, Tai WT, et al. Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther. 2011;337:155–161.
   PubMed Web of Science ®Google Scholar
• Zhai B, Hu F, Jiang X, et al. Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma. Mol Cancer Ther. 2014;13:1589–1598.
   PubMed Web of Science ®Google Scholar
• Fahmy RG, Dass CR, Sun LQ, et al. Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. Nat Med. 2003;9:1026–1032.
   PubMed Web of Science ®Google Scholar
• Kuo PL, Chen YH, Chen TC, et al. CXCL5/ENA78 increased cell migration and epithelial-to-mesenchymal transition of hormone-independent prostate cancer by early growth response-1/snail signaling pathway. J Cell Physiol. 2011;226:1224–1231.
   PubMed Web of Science ®Google Scholar
• Cabodi S, Morello V, Masi A, et al. Convergence of integrins and EGF receptor signaling via PI3K/Akt/FoxO pathway in early gene Egr-1 expression. J Cell Physiol. 2009;218:294–303.
   PubMed Web of Science ®Google Scholar
• Kim CG, Choi BH, Son SW, et al. Tamoxifen-induced activation of p21Waf1/Cip1 gene transcription is mediated by early growth response-1 protein through the JNK and p38 MAP kinase/Elk-1 cascades in MDA-MB-361 breast carcinoma cells. Cell Signal. 2007;19:1290–1300.
   PubMed Web of Science ®Google Scholar
• Furlan A, Kherrouche Z, Montagne R, et al. Thirty years of research on met receptor to move a biomarker from bench to bedside. Cancer Res. 2014;74:6737–6744.
   PubMed Web of Science ®Google Scholar
• Giordano S, Columbano A. Met as a therapeutic target in HCC: facts and hopes. J Hepatol. 2014;60:442–452.
   PubMed Web of Science ®Google Scholar